The Pathogenesis of Mycosis Fungoides

New England Journal of Medicine

Volumn 350, Issue 19, 2004, Pages 1978-1988

  Girardi, Michael ^a   Heald, Peter W ^a   Wilson, Lynn D ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; BEXAROTENE; CHLORAMBUCIL; CORTICOSTEROID; DENILEUKIN DIFTITOX; METHOTREXATE;

CLINICAL FEATURE; DISEASE ASSOCIATION; ELECTRON BEAM; HUMAN; MYCOSIS FUNGOIDES; NONHODGKIN LYMPHOMA; PATHOGENESIS; PHOTOTHERAPY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SKIN INFECTION; SUN EXPOSURE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; CELL CLONE; CLASSIFICATION; CUTANEOUS T CELL LYMPHOMA; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; PATHOLOGY; SKIN TUMOR;

CLONE CELLS; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOMA, T-CELL, CUTANEOUS; MYCOSIS FUNGOIDES; SKIN NEOPLASMS; T-LYMPHOCYTES;

EID: 2342531057     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMra032810     Document Type: Review

References (92)

1. Robert C, Kupper TS. Inflammatory skin diseases, T cells, and immune surveillance. N Engl J Med 1999;341:1817-28.
2. Weinstock MA, Horm JW. Mycosis fungoides in the United States: increasing incidence and descriptive epidemiology. JAMA 1988;260:42-6.
3. Weinstock MA, Gardstein B. Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality. Am J Public Health 1999;89:1240-4.
4. Morales Suarez-Varela MM, Llopis Gonzalez A, Marquina Vila A, Bell J. Mycosis fungoides: review of epidemiological observations. Dermatology 2000;201:21-8.
5. Heme KL, Talpur R, Breuer-McHam J, Champlin R, Duvic M. Cytomegalovirus seropositivity is significantly associated with mycosis fungoides and Sezary syndrome. Blood 2003;101:2132-6.
6. Willemze R, Kerl H, Sterry W, et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood 1997;90:354-71.
7. Sander CA, Flaig MJ, Jaffe ES. Cutaneous manifestations of lymphoma: a clinical guide based on the WHO classification. Clin Lymphoma 2001;2:86-100.
8. Berger CL, Warburton D, Raafat J, LoGerfo P, Edelson RL. Cutaneous T-cell lymphoma: neoplasm of T cells with helper activity. Blood 1979;53:642-51.
9. Latkowski JA, Heald PW. Cutaneous T cell lymphomas. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, eds. Fitzpatrick's dermatology in general medicine. 6th ed. Vol. 2. New York: McGraw-Hill, 2003:1537-58.
10. Bunn PA Jr, Lamberg SI. Report of the Committee on Staging and Classification of Cutaneous T-Cell Lymphomas. Cancer Treat Rep 1979;63:725-8.
11. Vonderheid EC, Bernengo MG, Burg G, et al. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol 2002;46:95-106.
12. Heald P, Rook A, Perez M, et al. Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy. J Am Acad Dermatol 1992;27:427-33.
13. Ferenczi K, Yawalkar N, Jones D, Kupper TS. Monitoring the decrease of circulating malignant T cells in cutaneous T-cell lymphoma during photopheresis and interferon therapy. Arch Dermatol 2003;139:909-13.
14. Jones D, Dang NH, Duvic M, Washington LT, Huh YO. Absence of CD26 expression is a useful marker for diagnosis of T-cell lymphoma in peripheral blood. Am J Clin Pathol 2001;115:885-92.
15. Scala E, Narducci MG, Amerio P, et al. T cell receptor-Vbeta analysis identifies a dominant CD60+ CD26-CD49d-T cell clone in the peripheral blood of Sezary syndrome patients. J Invest Dermatol 2002;119:193-6.
16. Diamandidou E, Colome-Grimmer M, Fayad L, Duvic M, Kurzrock R. Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. Blood 1998;92:1150-9.
17. Santucci M, Burg G, Feller AC. Interrater and intrarater reliability of histologic criteria in early cutaneous T-cell lymphoma: an EORTC Cutaneous Lymphoma Project Group study. Dermatol Clin 1994;12:323-7.
18. Bekkenk MW, Vermeer MH, Jansen PM, et al. Peripheral T-cell lymphomas unspecified presenting in the skin: analysis of prognostic factors in a group of 82 patients. Blood 2003;102:2213-9.
19. Santucci M, Pimpinelli N, Massi D, et al. Cytotoxic/natural killer cell cutaneous lymphomas: report of EORTC Cutaneous Lymphoma Task Force Workshop. Cancer 2003;97:610-27.
20. Glusac EJ, Shapiro PE, McNiff JM. Cutaneous T-cell lymphoma: refinement in the application of controversial histologic criteria. Dermatol Clin 1999;17:601-14.
21. Liu V, McKee PH. Cutaneous T-cell lymphoproliferative disorders: approach for the surgical pathologist: recent advances and clarification of confused issues. Adv Anat Pathol 2002;9:79-100.
22. Toro JR, Liewehr DJ, Pabby N, et al. Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma. Blood 2003;101:3407-12.
23. Hwang ST. Mechanisms of T-cell homing to skin. Adv Dermatol 2001;17:211-41.
24. Fuhlbrigge RC, Kieffer JD, Armerding D, Kupper TS. Cutaneous lymphocyte antigen is a specialized form of PSGL-1 expressed on skin-homing T cells. Nature 1997;389:978-81.
25. Campbell JJ, Haraldsen G, Pan J, et al. The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells. Nature 1999;400:776-80.
26. Reiss Y, Proudfoot AE, Power CA, Campbell JJ, Butcher EC. CC chemokine receptor (CCR)4 and the CCR10 ligand cutaneous T cell-attracting chemokine (CTACK) in lymphocyte trafficking to inflamed skin. J Exp Med 2001;194:1541-7.
27. Picker LJ, Michie SA, Rott LS, Butcher EC. A unique phenotype of skin-associated lymphocytes in humans: preferential expression of the HECA-452 epitope by benign and malignant T cells at cutaneous sites. Am J Pathol 1990;136:1053-68.
28. Heald PW, Yan SL, Edelson RL, Tigelaar R, Picker LJ. Skin-selective lymphocyte homing mechanisms in the pathogenesis of leukemic cutaneous T-cell lymphoma. J Invest Dermatol 1993;101:222-6.
29. Ferenczi K, Fuhlbrigge RC, Pinkus J, Pinkus GS, Kupper TS. Increased CCR4 expression in cutaneous T cell lymphoma. J Invest Dermatol 2002;119:1405-10.
30. Kakinuma T, Sugaya M, Nakamura Y, et al. Thymus and activation-regulated chemokine (TARC/CCL17) in mycosis fungoides: serum TARC levels reflect the disease activity of mycosis fungoides. J Am Acad Dermatol 2003;48:23-30.
31. Dietz SB, Whitaker-Menezes D, Lessin SR. The role of alpha E beta 7 integrin (CD103) and E-cadherin in epidermotropism in cutaneous T-cell lymphoma. J Cutan Pathol 1996;23:312-8.
32. Schechner JS, Edelson RL, McNiff JM, Heald PW, Pober JS. Integrins alpha4beta7 and alphaEbeta7 are expressed on epidermotropic T cells in cutaneous T cell lymphoma and spongiotic dermatitis. Lab Invest 1999;79:601-7.
33. Lu D, Duvic M, Medeiros LJ, Luthra R, Dorfman DM, Jones D. The T-cell chemokine receptor CXCR3 is expressed highly in low-grade mycosis fungoides. Am J Clin Pathol 2001;115:413-21.
34. Kallinich T, Muche JM, Qin S, Sterry W, Audring H, Kroczek RA. Chemokine receptor expression on neoplastic and reactive T cells in the skin at different stages of mycosis fungoides. J Invest Dermatol 2003;121:1045-52.
35. Bagot M, Wechsler J, Lescs MC, Revuz J, Farcet JP, Gaulard P. Intraepidermal localization of the clone in cutaneous T-cell lymphoma. J Am Acad Dermatol 1992;27:589-93.
36. Gellrich S, Lukowsky A, Schilling T, et al. Microanatomical compartments of clonal and reactive T cells in mycosis fungoides: molecular demonstration by single cell polymerase chain reaction of T cell receptor gene rearrangements. J Invest Dermatol 2000;115:620-4.
37. Yazdi AS, Medeiros LJ, Puchta U, Thaller E, Flaig MJ, Sander CA. Improved detection of clonality in cutaneous T-cell lymphomas using laser capture microdissection. J Cutan Pathol 2003;30:486-91.
38. Zackheim HS, Amin S, Kashani-Sabet M, McMillan A. Prognosis in cutaneous T-cell lymphoma by skin stage: long-term survival in 489 patients. J Am Acad Dermatol 1999;40:418-25.
39. Demierre MF, Kim YH, Zackheim HS. Prognosis, clinical outcomes and quality of life issues in cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 2003;17:1485-507.
40. Kim YH, Liu HL, Mraz-Gernhard S, Varghese A, Hoppe RT. Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. Arch Dermatol 2003;139:857-66.
41. Quiros P, Kacinski BM, Wilson LD. Extent of skin involvement as a prognostic indicator of disease free and overall survival in patients with T3 cutaneous T-cell lymphoma treated with total skin electron beam radiation therapy. Cancer 1996;77:1912-7.
42. Fraser-Andrews EA, Russell-Jones R, Woolford AJ, Wolstencroft RA, Dean AJ, Whittaker SJ. Diagnostic and prognostic importance of T-cell receptor gene analysis in patients with Sezary syndrome. Cancer 2001;92:1745-52.
43. Jones GW, Hoppe RT, Glatstein E. Electron treatment for cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995;9:1057-76.
44. Jones GW, Kacinski BM, Wilson LD, et al. Total skin electron radiation in the management of mycosis fungoides: consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group. J Am Acad Dermatol 2002;47:364-70.
45. Smith BD, Wilson LD. Management of mycosis fungoides. 2. Treatment. Oncology (Huntingt) 2003;17:1419-28.
46. Heald P. Clinical trials and efficacy assessment in the therapy of cutaneous T cell lymphoma. Ann N Y Acad Sci 2001;941:155-65.
47. Kieffer JD, Fuhlbrigge RC, Armerding D, et al. Neutrophils, monocytes, and dendritic cells express the same specialized form of PSGL-1 as do skin-homing memory T cells: cutaneous lymphocyte antigen. Biochem Biophys Res Commun 2001;285:577-87.
48. Hwang ST, Fitzhugh DJ. Aberrant expression of adhesion molecules by Sézary cells: functional consequences under physiologic shear stress conditions. J Invest Dermatol 2001;116:466-70.
49. Berger CL, Hanlon D, Kanada D, et al. The growth of cutaneous T-cell lymphoma is stimulated by immature dendritic cells. Blood 2002;99:2929-39.
50. Neish C, Charlry M, Jegasothy B, Tharp M, Deng JS. Proliferation cell nuclear antigen and soluble interleukin 2 receptor levels in cutaneous T cell lymphoma: correlation with advanced clinical diseases. J Dermatol Sci 1994;8:11-7.
51. Nagatani T, Matsuzaki T, Iemoto G, et al. Comparative study of cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma: clinical, histopathologic, and immunohistochemical analyses. Cancer 1990;66:2380-6.
52. Nielsen M, Nissen MH, Gerwien J, et al. Spontaneous interleukin-5 production in cutaneous T-cell lymphoma lines is mediated by constitutively activated Stat3. Blood 2002;99:973-7.
53. Eriksen KW, Kaltoft K, Mikkelsen G, et al. Constitutive STAT3-activation in Sezary syndrome: tyrphostin AG490 inhibits STAT3-activation, interleukin-2 receptdr expression and growth of leukemic Sezary cells. Leukemia 2001;15:787-93.
54. Brender C, Nielsen M, Kaltoft K, et al. STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma. Blood 2001;97:1056-62.
55. Mao X, Lillington D, Scarisbrick JJ, et al. Molecular cytogenetic analysis of cutaneous T-cell lymphomas: identification of common genetic alterations in Sezary syndrome and mycosis fungoides. Br J Dermatol 2002;147:464-75.
56. Vowels BR, Cassin M, Vonderheid EC, Rook AH. Aberrant cytokine production by Sezary syndrome patients: cytokine secretion pattern resembles murine Th2 cells. J Invest Dermatol 1992;99:90-4.
57. Papadavid E, Economidou J, Psarra A, et al. The relevance of peripheral blood T-helper 1 and 2 cytokine pattern in the evaluation of patients with mycosis fungoides and Sezary syndrome. Br J Dermatol 2003;148:709-18.
58. Kari L, Loboda A, Nebozhyn M, et al. Classification and prediction of survival in patients with the leukemic phase of cutaneous T cell lymphoma. J Exp Med 2003;197:1477-88.
59. Saed G, Fivenson DP, Naidu Y, Nickoloff BJ. Mycosis fungoides exhibits a Th1-type cell-mediated cytokine profile whereas Sezary syndrome expresses a Th2-type profile. J Invest Dermatol 1994;103:29-33.
60. Bagot M, Nikolova M, Schirm-Chabanette F, Wechsler J, Boumsell L, Bensussan A. Crosstalk between tumor T lymphocytes and reactive T lymphocytes in cutaneous T cell lymphomas. Ann N Y Acad Sci 2001;941:31-8.
61. Vonderheid EC, Zhang Q, Lessin SR, et al. Use of serum soluble interleukin-2 receptor levels to monitor the progression of cutaneous T-cell lymphoma. J Am Acad Dermatol 1998;38:207-20.
62. Kantor AF, Curtis RE, Vonderheid EC, van Scott EJ, Fraumeni JF Jr. Risk of second malignancy after cutaneous T-cell lymphoma. Cancer 1989;63:1612-5.
63. Gottlieb SL, Gilleaudeau P, Johnson R, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1995;1:442-7.
64. Olsen E, Duvic M, Frankel A, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001;19:376-88.
65. Whittaker S. Molecular genetics of cutaneous lymphomas. Ann N Y Acad Sci 2001;941:39-45.
66. Scarisbrick JJ, Mitchell TJ, Calonje E, Orchard G, Russell-Jones R, Whittaker SJ. Microsatellite instability is associated with hypermethylation of the hMLH1 gene and reduced gene expression in mycosis fungoides. J Invest Dermatol 2003;121:894-901.
67. Wood GS, Tung RM, Haeffner AC, et al. Detection of clonal T-cell receptor gamma gene rearrangements in early mycosis fungoides/Sézary syndrome by polymerase chain reaction and denaturing gradient gel electrophoresis (PCR/DGGB). J Invest Dermatol 1994;103:34-41.
68. Benhattar J, Delacretaz F, Martin P, Chaubert P, Costa J. Improved polymerase chain reaction detection of clonal T-cell lymphoid neoplasms. Diagn Mol Pathol 1995;4:108-12.
69. Vega F, Luthra R, Medeiros LJ, et al. Clonal heterogeneity in mycosis fungoides and its relationship to clinical course. Blood 2002;100:3369-73.
70. Hoppe RT, Medeiros LJ, Warnke RA, Wood GS. CD8-positive tumor-infiltrating lymphocytes influence the long-term survival of patients with mycosis fungoides. J Am Acad Dermatol 1995;32:448-53.
71. Heald P, Yan SL, Edelson R. Profound deficiency in normal circulating T cells in erythrodermic cutaneous T-cell lymphoma. Arch Dermatol 1994;130:198-203.
72. Lu D, Patel KA, Duvic M, Jones D. Clinical and pathological spectrum of CD8-positive cutaneous T-cell lymphomas. J Cutan Pathol 2002;29:465-72. [Erratum, J Cutan Pathol 2003;30:222.]
73. Lu D, Patel KA, Duvic M, Jones D. Clinical and pathological spectrum of CD8-positive cutaneous T-cell lymphomas. J Cutan Pathol 2002;29:465-72. [Erratum, J Cutan Pathol 2003;30:222.]
74. Yawalkar N, Ferenczi K, Jones DA, et al. Profound loss of T-cell receptor repertoire complexity in cutaneous T-cell lymphoma. Blood 2003;102:4059-66.
75. Dereure O, Levi E, Vonderheid EC, Kadin ME. Infrequent Fas mutations but no Bax or p53 mutations in early mycosis fungoides: a possible mechanism for the accumulation of malignant T lymphocytes in the skin. J Invest Dermatol 2002;118:949-56.
76. van Doorn R, Dijkman R, Vermeer MH, Starink TM, Willemze R, Tensen CP. A novel splice variant of the Fas gene in patients with cutaneous T-cell lymphoma. Cancer Res 2002;62:5389-92.
77. Ni X, Hazarika P, Zhang C, Talpur R, Duvic M. Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape? Clin Cancer Res 2001;7:2682-92.
78. Edelson R, Berger C, Gasparro F, et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy: preliminary results. N Engl J Med 1987;316:297-303.
79. Berger CL, Xu AL, Hanlon D, et al. Induction of human tumor-loaded dendritic cells. Int J Cancer 2001;91:438-47.
80. Berger CL, Longley J, Hanlon D, Girardi M, Edelson R. The clonotypic T cell receptor is a source of tumor-associated antigens in cutaneous T cell lymphoma. Ann N Y Acad Sci 2001;941:106-22.
81. Winter D, Fiebiger E, Meraner P, et al. Definition of TCR epitopes for CTL-mediated attack of cutaneous T cell lymphoma. J Immunol 2003;171:2714-24.
82. Usener D, Schadendorf D, Koch J, Dubel S, Eichmuller S. cTAGE: a cutaneous T cell lymphoma associated antigen family with tumor-specific splicing. J Invest Dermatol 2003;121:198-206.
83. Girardi M, Berger C, Hanlon D, Edelson RL. Efficient tumor antigen loading of dendritic antigen presenting cells by transimmunization. Technol Cancer Res Treat 2002;1:65-9.
84. Olsen EA, Bunn PA. Interferon in the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995;9:1089-107.
85. Suchin KR, Cucchiara AJ, Gottlieb SL, et al. Treatment of cutaneous T-cell lymphoma with combined immunomodulatory therapy: a 14-year experience at a single institution. Arch Dermatol 2002;138:1054-60.
86. Sanz MA, Martín G, Díaz-Mediavilla J. All-trans-retinoic acid in acute promyelocytic leukemia. N Engl J Med 1998;338:393.
87. Fontana JA, Rishi AK. Classical and novel retinoids: their targets in cancer therapy. Leukemia 2002;16:463-72.
88. Zhang C, Hazarika P, Ni X, Weidner DA, Duvic M. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res 2002;8:1234-40.
89. Cheng SX, Kupper T. A new rexinoid for cutaneous t-cell lymphoma. Arch Dermatol 2001;137:649-52.
90. Duvic M, Martin AG, Kim Y, et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001;137:581-93.
91. Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001;19:2456-71.
92. Duvic M, Apisarnthanarax N, Cohen DS, Smith TL, Ha CS, Kurzrock R. Analysis of long-term outcomes of combined modality therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 2003;49:35-49.